OGN Overview
Upcoming Projects (OGN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (OGN)
-
Third View: Discussing the recent FDA approval of Organon's VTAMA (tapinarof), a 1% cream for the treatment of atopic dermatitis in adults and children 2 years of age and older.
Ticker: OGN
Executed On: Dec 19, 2024 at 12:15 PM EST -
Second View: Discussing the recent FDA approval of Organon's VTAMA (tapinarof), a 1% cream for the treatment of atopic dermatitis in adults and children 2 years of age and older.
Ticker: OGN
Executed On: Dec 18, 2024 at 11:00 AM EST -
Discussing the recent FDA approval of Organon's VTAMA (tapinarof), a 1% cream for the treatment of atopic dermatitis in adults and children 2 years of age and older.
Ticker: OGN
Executed On: Dec 17, 2024 at 01:45 PM EST -
A Third Opinion: Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Feb 21, 2024 at 05:00 PM EST -
A Second Opinion: Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Feb 01, 2024 at 10:00 AM EST -
Discussing the mental health side effects and the use of Singulair (montelukast) for treating pediatric asthma.
Tickers: OGN, MRK
Executed On: Jan 18, 2024 at 03:00 PM EST
Upcoming & Overdue Catalysts (OGN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (OGN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
